Skip to Content

Davanat FDA Approval Status

FDA Approved: No
Brand name: Davanat
Company: Galectin Therapeutics Inc.
Treatment for: Targeted Drug Delivery

Davanat is a polysaccharide polymer comprised of mannnose and galactose in development for the targeted delivery of drugs used in the treatment of cancer.

Development Timeline for Davanat

DateArticle
Sep 15, 2008Pro-Pharmaceuticals Submits Data to FDA for Davanat NDA to Treat Advanced Colorectal Cancer
May 20, 2008Pro-Pharmaceuticals Announces Submission of Drug Master File forDavanat to FDA
May  1, 2008Pro-Pharmaceuticals Updates NDA Filing for Davanat
Dec 19, 2007Pro-Pharmaceuticals Selects SAFC, a Division of Sigma-Aldrich, toSubmit a Drug Master File
Jun 11, 2007Pro-Pharmaceuticals Submits Data to Begin a 505 (b)(2) Filing withthe FDA for a New Formulation of Irinotecan to be Co-administeredwith Davanat as a Functional Excipient
Apr 11, 2007Pro-Pharmaceuticals Receives Letter from the FDA for New DrugApplication for Davanat/ 5-FU
Feb  7, 2007Pro-Pharmaceuticals' Begins Process of New Drug Application Submission with the FDA for Co-administration of Davanat with 5-FU in Cancer Patients

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.